Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price gapped up before the market opened on Monday . The stock had previously closed at $55.80, but opened at $58.15. Keros Therapeutics shares last traded at $54.79, with a volume of 32,041 shares traded.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of recent research reports. Bank of America cut their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer began coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. Truist Financial restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Guggenheim started coverage on Keros Therapeutics in a research note on Monday. They set a “buy” rating and a $96.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $90.63.

Keros Therapeutics Trading Down 2.2 %

The firm has a 50 day moving average price of $49.53 and a 200-day moving average price of $52.97. The firm has a market cap of $1.97 billion, a PE ratio of -10.58 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the prior year, the firm posted ($1.27) EPS. Equities analysts forecast that Keros Therapeutics, Inc. will post -4.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares in the company, valued at $5,260,163.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 22.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth about $27,367,000. Redmile Group LLC acquired a new position in Keros Therapeutics in the 1st quarter valued at $36,576,000. Darwin Global Management Ltd. boosted its holdings in shares of Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after purchasing an additional 375,523 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Keros Therapeutics by 47.9% in the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock valued at $27,809,000 after purchasing an additional 226,674 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after purchasing an additional 176,803 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.